Hester Biosciences Ltd
Hester Biosciences Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Consolidated performance is strong, giving confidence in strategies across geographies and portfolios. Consolidated performance shows strong confidence due to effective strategies across geographies and portfolios.
From Hester Biosciences Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Consolidated performance is strong, giving confidence in strategies across geographies and portfolios.
- Optimism about growth in remaining FY '26 quarters with normalization of institutional demand.
- Increased momentum expected in newer markets, especially in Petcare and Poultry portfolios.
- Expansion in African markets with a focus on localized products to drive demand.
- Efforts underway to repurpose BSL-3 facility to broaden animal vaccine range.
- Continued growth expected from feed supplements, disinfectants, and avian influenza vaccine launches.
- Africa operations showing a positive turnaround and profitability supporting consolidated growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The BSL-3 facility, initially developed for COVID bulk antigen manufacturing, is currently being repurposed for expanding the animal vaccine product range.
- Permission for repurposing the BSL-3 facility is expected within the next few months.
- The firm is focused on optimizing capacity utilization across its three plants (including Nepal) to meet rising demand, particularly in Africa.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There are deferred execution and timing delays in institutional orders, especially for large immunization programs like PPR and lumpy skin disease, causing a dip in standalone performance.
- These deferred orders are not cancellations but postponements, with expectations of execution picking up from Q2 FY '26 onwards.
- The PPR vaccine is mainly a tender business, and the company is in regular follow-up with African agencies managing eradication programs.
- New registrations and business are coming in from various African countries, indicating a growing order pipeline.
2 more points management made on order book & pipeline
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Hester Biosciences Ltd Q1 FY26 results?
Consolidated performance is strong, giving confidence in strategies across geographies and portfolios. Consolidated performance shows strong confidence due to effective strategies across geographies and portfolios.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
The BSL-3 facility, initially developed for COVID bulk antigen manufacturing, is currently being repurposed for expanding the animal vaccine product range.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.